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Abstract 
Outcome of patients with multiple myeloma (MM) has greatly improved with the use of autologous 
stem cell transplantation (ASCT) and new agents, such as immunomodulatory drugs (thalidomide 
and lenalidomide) and proteasome inhibitors (bortezomib). When compared to conventional 
chemotherapy, high-dose melphalan with ASCT significantly improved response rates and 
progression-free survival, while overall survival benefit was not consistent across all trials. ASCT is 
considered the standard treatment for patients who are younger than 65 years and who do not have 
limiting comorbidities. New, effective agents have been introduced as part of induction, 
consolidation and maintenance treatments within ASCT and in combinations with chemotherapy for 
patients not eligible for ASCT. The remarkable results obtained with these regimens are questioning 
the role of ASCT for newly diagnosed MM patients. This article aims to delineate the role of ASCT 
in the era of novel agents based on the results of recent clinical trials.  
 
1.Introduction 
Autologous stem cell transplantation (ASCT) is the standard treatment for newly diagnosed 
multiple myeloma (MM) patients younger than 65 years and/or eligible for high-dose 
chemotherapy. Before the introduction of novel agents, such as immunomodulatory drugs (IMiDs; 
thalidomide and lenalidomide) and proteasome inhibitors (bortezomib), high-dose melphalan with 
ASCT significantly improved response rates and progression-free survival (PFS) in comparison 
with conventional chemotherapy, with conflicting results in terms of overall survival (OS) (1-4). 
Newer agents were later incorporated both in the transplant and non-transplant settings, and 
significantly improved patient outcome (5). The depth and the duration of response obtained with 
these new approaches correlated with a PFS benefit and, in several studies, also with an OS 
improvement. This was evident in both young patients receiving ASCT, and elderly patients 
receiving conventional chemotherapy in combination with new agents (6-10). It has been suggested 
that the optimal treatment strategy should aim at achieving sustained complete response (CR) (11).  
Yet, long-term control of the disease has been shown also in patients not achieving high-quality 
responses, which may reflect changes in host immune status or a clonal heterogeneity of the disease 
at diagnosis. Thus patients may also benefit from a less intensive treatment, that can be able to 
control, if not eradicate, the disease. The remarkable results obtained in the non-transplant setting 
questioned the role of ASCT for newly diagnosed MM patients. On the other hand, there is 
increasing evidence that the selective pressure of treatment may be responsible for emergence of 
different MM sub-clones leading to drug resistance at more advanced stages (12). If this will be 
confirmed, it could be reasonable to give the most effective and intensive treatment, that is ASCT, 
at the early phases of disease, when the probability of reaching long-lasting remissions is higher.  
This article aims to delineate the role of ASCT in the era of novel agents based on the results of 
recent clinical trials.  
 
2. New agents in the transplant setting. 
Novel agents have been incorporated in the pre-transplant induction and post-transplant 
consolidation and maintenance regimens. Data about the impact of induction therapy on 
transplantation are quite limited and further investigation is certainly needed.  
2.1 Induction regimens 
Vincristine-doxorubicin-dexamethasone (VAD) was used for many years as pre-transplant 
induction therapy, inducing an overall response rate (ORR) of 54% with a CR rate of 2% (13). 
Novel agents (thalidomide and bortezomib) were then tested in combination with dexamethasone as 
induction regimens before ASCT. Thalidomide plus dexamethasone (TD) increased response rates 
in comparison with VAD or thalidomide alone: the at least very good partial response (VGPR) rate 
was 30% with TD vs 15% with VAD (P=0.003) (14); the ORR was 72% with TD vs 36% with 
thalidomide alone (15). Similarly, bortezomib plus dexamethasone (VD) showed an ORR of 78% in 
comparison with 63% with VAD (P<0.001) (16). Two randomized phase III trials evaluated a short 
course of lenalidomide and dexamethasone (Rd) as induction before ASCT, showing an ORR of 
76%, including 29% of patients achieving at least a VGPR (17,18). 
Better results were achieved with three-drug combinations including thalidomide or bortezomib 
plus conventional chemotherapeutic agents, such as doxorubicin and cyclophosphamide (13,19,20). 
A significant improvement in ORR in comparison with VAD was reported with doxorubicin in 
combination with thalidomide-dexamethasone (TAD) (88% vs 79%, P=0.005) (19) and doxorubicin 
in combination with bortezomib and dexamethasone (PAD) (78% vs 54%, P<0.001) (13). 
Cyclophosphamide in combination with thalidomide-dexamethasone (CTD) significantly enhanced 
the ORR in comparison with cyclophosphamide-VAD (83% vs 71%, P<0.0001) (20).  
 The three-drug combination bortezomib-thalidomide-dexamethasone (VTD) was compared with 
TD and multi-agent chemotherapy (21,22). A significant improvement in the CR rate was detected 
with VTD compared with TD (35% vs 14%, P=0.0001) and with multi-agent chemotherapy (35% 
vs 21%, P=0.01) (21). Another study compared the triplet VTD with TD and showed a higher CR 
rate with the three-drug regimen (31% vs 11%, P<0.001) (22). A recent phase 2 trial showed a 
promising VGPR rate of 58% after induction with bortezomib-lenalidomide-dexamethasone (VRD) 
(23).  
Two meta-analyses of data from phase III studies in ASCT-eligible patients with previously 
untreated MM demonstrated that bortezomib-containing induction regimens results in a 
significantly improved ORR compared with non bortezomib-containing regimens (24,25).  
Two phase II studies did not show significant advantages with four-drug bortezomib-based 
regimens in comparison with three-drug combinations (26,27). 
In all the trials previously reported, ASCT further improved the depth of response as shown in table 
1. Table 2 reports safety data of selected induction regimens.  
 
2.2 Consolidation regimens 
In the past, a second ASCT was administered to consolidate the response achieved after a first 
course of high-dose melphalan followed by ASCT. Before the introduction of novel agents, several 
trials showed a prolonged event-free survival (EFS) with double ASCT vs single ASCT (28-30). 
Results of a subgroup analysis of one of those trials, reported an improved OS only in patients 
achieving less than a VGPR after the first ASCT (28). The role of double ASCT in the era of novel 
agents is not yet defined. In the HOVON-65/GMMG-HD4 study, patients were randomized to 
receive induction with PAD vs VAD followed by ASCT. Per protocol, one or two cycles of high-
dose melphalan were planned. In patients who received single ASCT, the 5-year OS was 55% in 
both PAD and VAD arms (P=0.39), while in those who received tandem ASCT the 5-year OS was 
70% with PAD and 55% with VAD (P=0.07), thus suggesting an advantage with the tandem option 
(13). Yet, P-values were not significant and results were derived from a subgroup analysis. In 
addition, patients were not randomized to receive either tandem or single ASCT, but the choice was 
dependent on country practice (13). Post-ASCT consolidation with bortezomib and IMiDs is 
currently under evaluation. In a randomized phase III trial, bortezomib was compared with no 
consolidation therapy in bortezomib naïve patients (31). The progression-free survival (PFS) from 
randomization was 27 months for the bortezomib group and 20 months for the control group 
(P=0.05), while no difference in OS was seen (31). In another trial, VTD consolidation was 
administrated in patients achieving at least a VGPR after double ASCT. This strategy further 
improved the depth of response: the CR rate increased from 15% to 49% and molecular remission 
rate increased from 3% to 18% (8,32). Of note, the two previous studies included newly diagnosed 
patients who did not receive novel-agent based induction. A consolidation approach using the same 
regimens employed during induction (VTD vs TD) was assessed after double ASCT (33). VTD 
consolidation increased the CR/nCR rate from 63% to 73%; most of the patients who improved to 
CR after VTD consolidation had achieved at least a VGPR after transplantation. The 3-year PFS 
was superior with VTD in comparison with TD (60% vs 48%, P=0.042) (33). Similarly, a recently 
published trial showed an improvement in post-ASCT response rate with VRD consolidation 
(VGPR 70% after ASCT to 87% after consolidation); as in the previous study, the same regimen 
was administered as pre-transplant induction (23). Four cycles of lenalidomide-prednisone have 
been adopted as consolidation after double ASCT in patients receiving PAD induction. This 
approach increased the CR rate from 33% to 48%; also in this study, the major benefit was noticed 
in patients who achieved VGPR after transplantation (34). These data show that intensification with 
bortezomib and/or IMiDs improves response rates, and the improvement was mainly seen in 
patients with sensitive disease. The total therapy (TT) study evaluated the impact of the addition of 
thalidomide (TT2) or bortezomib (TT3) to a multi-agent chemotherapy and high-dose melphalan 
program supported by double ASCT (35). In this TT study, novel agents were administered both in 
the pre-transplant and in the post-transplant settings. In the TT3 the cumulative frequency of CR 
increased during the different treatment phases reaching 56% at 2 years (36,37).  
 
2.3 Maintenance regimens 
The optimal maintenance regimen should aim at prolonging the remission duration without 
affecting the patient’s quality of life. Maintenance treatments with alkylating agents, steroids or 
interferon were tested in the pre-novel agents era (38-41). In one study,  maintenance with 
prednisone every other day improved PFS and OS, (38) yet, in another study, no benefit was seen 
with single agent dexamethasone.(39) Data are therefore insufficient to recommend corticosteroids 
maintenance therapy. 
In six different randomized trials, thalidomide maintenance was used post-ASCT: thalidomide-
based maintenance arm was compared with alpha-interferon, dexamethasone, pamidronate, 
prednisone, or observation in the different trials (19,35,42-45). A recent meta-analysis showed a 
reduced risk of progression (HR 0.64, P<0.001) and death (HR 73, P=0.002) with thalidomide 
maintenance (46). However, a significant rate of grade 3-4 neuropathy (7-19%) limited the long-
term use of this drug (the rate of discontinuation reached 52%) (47). The lack of tolerability of 
thalidomide likely resulted from the doses used in the source studies and these data suggest that 
other options than continuous therapy with thalidomide should be recommended. Only one trial 
evaluated post-ASCT bortezomib maintenance. Patients randomized to PAD or VAD induction 
followed by ASCT received bortezomib or thalidomide maintenance respectively. In a landmark 
analysis, bortezomib maintenance significantly improved the CR/nCR rate from 31% to 49% and 
reduced the risk of progression (P=0.04) and death (P=0.05). The rate of grade 3-4 peripheral 
neuropathy was 5% with bortezomib maintenance and 8% with thalidomide maintenance, the 
incidence of grade 3-4 infections was 24% and 18% in the two groups, respectively (13). However, 
these data should be interpreted with caution considering that patients received different induction 
regimens. Three trials evaluated lenalidomide maintenance after ASCT (17,47,48). In two trials 
lenalidomide was employed after ASCT in newly diagnosed patients who received VAD or novel 
agent-based combinations at induction (47,48); in the IFM0502 trial, consolidation with 
lenalidomide was administered after ASCT, and lenalidomide was then given up to 2 years (47); 
whereas, in the CALGB 100104 trial no consolidation was planned and lenalidomide maintenance 
was continued until progression (48). In the GIMEMA MMRV-209 trial, all patients received 
induction with Rd, afterwards they were randomized to consolidation with ASCT or no ASCT, and 
finally to lenalidomide maintenance or no maintenance (17). The median follow-up period of these 
3 trials was different (range 18-51.2 months) and this further limits the comparison of the results. 
Despite the differences in the trial designs and treatments, a significant reduction in the risk of 
progression was reported with lenalidomide maintenance compared with no maintenance (HR range 
0.47-0.50) (17,47,48). Only the CALGB 1000104 trial also showed a significant reduction in the 
risk of death (48). The main grade 3-4 adverse events during maintenance with lenalidomide were 
neutropenia (23-51%), and infections (6-13%). Lenalidomide maintenance raised some conern 
second primary malignancies (SPM). The incidence of SPM with lenalidomide maintenance was 
4.3-8% vs 2.6-4.3% with placebo/no maintenance (17,47,48). The use of lenalidomide after and 
with oral melphalan could be a possible explanation for the increased incidence of SPM, as 
suggested by the results of a recent meta-analysis (49). In the different studies, however, the 
advantage associated with lenalidomide maintenance seems to outweigh the risk of SPM.  
 
3.Non-transplant setting 
Impressive results were achieved also with novel agents used for the treatment of elderly patients 
not eligible for ASCT. This provided the rationale to compare novel agent-based regimens with the 
more intensive approach ASCT, commonly associated with a higher rate of toxicity. Here follows a 
brief description of the most common regimens including novel agents adopted in the non-
transplant setting.  
A meta-analysis of six randomized trials comparing melphalan-prednisone-thalidomide (MPT) with 
melphalan-prednisone (MP) improved the median PFS (20.3 vs 14.9 months, P<0.0001) and OS 
(39.3 vs 32.7 months, P=0.004) with MPT (50). The combination bortezomib-melphalan-
prednisone (VMP) improved the median time to progression (24 vs 16.6 months, P<0.001) and OS 
(56.4 vs 41 months, P<0.001) in comparison with MP (51,52). A more intensive regimen including 
2 novel agents was explored in a phase III trial. VMP plus thalidomide followed by bortezomib-
thalidomide maintenance (VMPT-VT) was compared with VMP alone. The 3-year PFS (56% vs 
41%, P=0.008) and the 5-year OS (61% vs 51%, P=0.01) were significantly improved with the four-
drug combination (53,54). In another study bortezomib-thalidomide-prednisone (VTP) vs VMP 
inductions were followed by VT or bortezomib-prednisone (VP) maintenance. The median PFS was 
32 months for VMP and 33 months for VTP (P=0.09). VMP significantly prolonged the median OS 
in comparison with VTP (63 vs 43 months; P=0.01) (55,56). Melphalan-prednisone-lenalidomide 
followed by lenalidomide maintenance (MPR-R) prolonged the median PFS by 17 months in 
comparison to MPR and MP alone (31 vs 14 vs 13 months, P<0.001), highlighting the impact of 
post-induction maintenance in elderly patients (57). Continuous treatment with lenalidomide and 
dexamethasone showed prolonged PFS and OS in comparison with MPT (58). Tables 3 and 4 
present efficacy and safety data of selected regimens in the non-transplant setting.  
 4.Does the introduction of novel agents challenge the role of transplantation? 
The first trial that tried to answer this question compared MPT vs reduced-intensity ASCT in an 
elderly population of patients. Patients randomized to reduced-intensity ASCT received induction 
with VAD and no novel agent was administered, which was a limitation of that study. In addition, a 
higher rate of toxic deaths was reported during the first three months of treatment in the reduced-
intensity ASCT arm (therefore related to the induction regimen and not to ASCT itself) and this 
may have negatively affected the final results. MPT showed a significant reduction in the risk of 
progression (HR 0.54, P=0.0002) and the risk of death (HR 0.59, P=0.027) in comparison with 
reduced intensity ASCT (59). Despite its limitations, this study questioned the role of ASCT in the 
era of new drugs. The comparison of studies conducted in patients younger than 65 years versus 
those conducted in patients older than 65 years is however difficult. Recently, the first prospective 
randomized trial comparing combination chemotherapy including novel agents vs ASCT has been 
performed. Patients received Rd induction therapy and were then randomized to MPR or tandem 
ASCT. The median PFS was significantly longer for patients randomized to tandem ASCT than for 
those randomized to MPR (43.0 vs 22.4 months, P<0.001). Tandem ASCT also improved the 4-year 
OS rate (81.6% vs. 65.3%, P=0.02) (17). In a similar study, 390 patients received Rd induction 
regimen and were then randomized to receive tandem ASCT or cyclophosphamide–lenalidomide-
dexamethasone, followed by lenalidomide or lenalidomide plus prednisone maintenance therapy. 
Preliminary results showed a reduced risk of progression for patients who received ASCT (3-year 
PFS: 60% vs 38%, P=0.003) (18).  Two ongoing large studies are currently enrolling patients. In the 
IFM/DFCI2009 study, 1,000 patients are receiving VRD induction and are then randomized to 
continue VRD treatment or to receive ASCT plus VRD consolidation. Subsequently, patients will 
receive lenalidomide maintenance (CT.gov NCT01191060; NCT01208662). In the EMN02 study 
1,500 patients are receiving VCD induction and are then randomly assigned to VMP or ASCT, and 
further randomized to receive consolidation/ no consolidation with VRD, followed by lenalidomide 
maintenance (CT.gov NCT01208766). 
In the majority of the previously described trials, patients who did not receive ASCT upfront will 
receive ASCT at relapse. These trials will therefore also try to define the best timing of ASCT, 
upfront or at first relapse. Before the introduction of novel agents, several randomized trials 
confirmed the PFS benefit with early ASCT in comparison with conventional chemotherapy. 
However, in 3 randomized studies, OS was similar whether ASCT was performed early or as 
salvage therapy at relapse (2-4). Despite similar OS (64.6 vs 64 months, P=0.92), early ASCT 
improved the average time without symptoms (27.8 vs 22.3 months) and reduced treatment-related 
toxicities and discontinuation compared with late ASCT in one trial (3). Yet, in most of these trials, 
patients in the control arm did not have full access to novel agents. 
 In the era of new agents, to date only the results of two trials comparing early vs delayed ASCT are 
available. A recent pooled analysis including these two randomized trials was performed. The 
pooled analysis evaluated not only PFS and OS, but also PFS2 (survival from randomization to 
progression on or after second line therapy), to better analyze the role of delayed transplantation. 
The pooled analysis showed an improvement in PFS (3-year 59% vs 35%, P<0.001) in PFS2 (3-
year 77% vs 68%, P=0.012) and OS (4-year 83%  vs 72%, P=0.096) – although the latter was not 
statistically significant - in patients receiving early ASCT (60) 
 
5.Conclusions and future perspectives 
The introduction of effective regimens including bortezomib and IMiDs has greatly improved the 
outcome observed with ASCT in young MM patients. The data from the prospective trials 
performed to date suggest that the best available strategy to achieve high CR rate, to prolong 
response duration and survival consists in a sequential approach including induction with 3-drug, 
bortezomib-based combinations followed by ASCT and consolidation/maintenance with IMiDs or 
proteasome inhibitors. A major drawback of the majority of the previously described trials is the 
fact that none of them was powered to assess OS. OS results may be affected by effective second-
line therapy that dilutes the ability to dissect out the role of transplant vs no transplant. The impact 
of ASCT vs no ASCT could be also partly related to the number of therapeutic options available in 
different parts of the world. Obviously in the setting of limited treatment options, ASCT may play a 
more important role than in parts of the world where patients have a wider variety of treatments. 
Despite these considerations, available results suggest that upfront ASCT still remains a necessary 
component of therapy if compared with conventional chemotherapy plus IMiDs. The role of ASCT 
in comparison with bortezomib plus chemotherapy or IMiDs is currently under evaluation. The 
results of ongoing studies (IFM/DFCI2009 and EMN02) are awaited and will help clarify the role 
of ASCT in the era of new drugs.   
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TABLE 1. Transplant setting: efficacy of selected sequential approaches. Improvement in response rates observed with 
induction, transplant, consolidation-maintenance regimens and survival data 
 
REGIMEN PATIENTS CR  (%) PFS OS  
VD induction 
MEL 200
16
 
240 
6* 
40°* 
50% at 36 months 81% at 36 months 
PAD induction 
MEL 200 
V maintenance
13
 
413 
7 
21 
36 
50% at 35 months 61% at 60 months 
PAD induction 
MEL 100 
RP consolidation 
R maintenance
34
 
102 
12 
33 
48 
53 
43% at 60 months 
63% at 60 months 
 
VTD induction 
MEL 200 
VTD consolidation
33
 
160 
23* 
49* 
61* 
62% at 60 months 90% at 36 months 
TD induction 
MEL 200 
TD consolidation
33
 
161 
6* 
40* 
47* 
49% at 60 months 88% at 36 months 
RD induction 
MEL 200 
R maintenance
17
 
399 
141 
126 
8 
16 
36 
50% at 55 months 79% at 60 months 
TAD induction 
MEL 200 
T maintenance
19
 
268 
3 
14 
31 
50% at 34 months 50% at 73 months 
VTD induction 
MEL 200
21
 130 
35 
46 50% at 56 months 74% at 48 months 
VRD induction 
MEL 200 
VRD consolidation 
R maintenance
23
 
31 
23 
47 
50 
- 
77% at 36 months 100% at 36 months 
 
CR, complete response; Mel 100, melphalan 100 mg/m2; MEL 200, melphalan 200 mg/m2; OS, overall survival; PAD, bortezomib-adriamicyn-
dexamethasone; PFS, progression-free survival; R, lenalidomide; RD, lenalidomide-dexamethasone; RP, lenalidomide-prednisone; T, thalidomide; 
TAD, thalidomide-adriamicyn-dexamethasone; TD, thalidomide-dexamethasone; V, bortezomib; VD, bortezomib-dexamethasone; VTD, bortezomib-
thalidomide-dexamethasone. 
° ≥near CR; * Data in the per protocol population. In all the other studies, data refer to the intention-to treat population; -  Data not available. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Transplant setting: Safety (grade 3-4 adverse events) of selected pre transplant induction and post transplant consolidation-maintenance regimens  
 
REGIMEN NEUTROPENIA 
(%) 
THROMBOCYTOPENIA 
(%) 
ANEMIA 
(%) 
THROMBOEMBOLISM 
(%) 
PN 
(%) 
INFECTION 
(%) 
SPM 
(%) 
INDUCTION 
VD
16
  5 3 4 2 7 9 - 
PAD
13-34
 3-10 10-17 3-8 4-5 16-24 17-26 - 
VTD
21,22
 10 8 - 3-12 10-12 3-21 - 
TD
22
 - - - 15 4 4 - 
TAD
19
 - - - 3 31§ - - 
RD
17
 9 3 6 3 - 6 0.3 
VRD
23*
 35 13 3 - - - - 
CONSOLIDATION 
VTD
33
 - 5** - 1 1 1 - 
TD
33
 - 0** - 1 0 3 - 
RP
34
 19 15 - 3 - - - 
MAINTENANCE 
V
13
  0 4 1 1 5 24 - 
T
13
 1 2 1 1 8 18  
R
17,47,48
 23-51 4-14 2-5 2-3 1 6-8 4.3-8 
 
 PAD, bortezomib-adriamicyn-dexamethasone; PN, peripheral neuropathy; R, lenalidomide; RD, lenalidomide-dexamethasone; RP, lenalidomide-prednisone; T, thalidomide; TAD, thalidomide-adriamycin-dexamethasone;  
TD, thalidomide-dexamethasone; V, bortezomib; VD, bortezomib-dexamethasone; VRD, bortezomib-lenalidomide-dexamethasone; VTD, bortezomib-thalidomide-dexamethasone. 
* Data about induction or consolidation, as reported in the original study; ** All grade events;  -  Data not available; § Grade 2 to 4. 
 
 
 
 
 
 
 
 
 
 
 
TABLE 3. Non transplant setting: efficacy of selected regimens  
 
REGIMEN PATIENTS CR (%) PFS OS  
MPT induction
50
 1685 25° 50% at 20 months 50% at 39 months 
VMP induction
52
 344 30 50% at 24 months* 68% at 36 months 
VMP induction
55,56
 130 20 50% at 32 months 50% at 63 months 
VMPT induction 
VT maintenance
54
 
254 38 
42 
50% at 35 months 61% at 60 months 
MPR induction 
R maintenance
17
 
152 10 
33° 
50% at 31 months 70% at 36 months 
VTP induction
55
 130 28 50% at 33 months 50% at 43 months 
Rd continuously
58
 535 15 50% at 26 months 59% at 60 months 
 
CR, complete response; MPR, melphalan-prednisone-lenalidomide; MPT, melphalan-prednisone-thalidomide; OS, overall survival; PFS, progression-
free survival; R, lenalidomide; Rd, lenalidomide-dexamethasone; VMP, bortezomib-melphalan-prednisone; VMPT, bortezomib-melphalan-
prednisone-thalidomide; VP, bortezomib-prednisone; VT, bortezomib-thalidomide; VTP, bortezomib-thalidomide-prednisone.  
° ≥ Very good partial response rate; * Time to progression.. 
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TABLE 4. NON TRANSPLANT SETTING: SAFETY (GRADE 3-4 ADVERSE EVENTS) OF SELECTED INDUCTION AND MAINTENANCE 
REGIMENS 
 
 
 
REGIMEN NEUTROPENIA 
(%) 
THROMBOCYTOPENIA 
(%) 
ANEMIA 
(%) 
THROMBOEMBOLISM 
(%) 
PN 
(%) 
INFECTION 
(%) 
SPM 
(%) 
INDUCTION 
MPT
50*
 16-48 3-14 3-14 2-12 2-9 10-28 - 
VMP
51,54,56
  28-40 20-37 10-19 <1-2 4-13 7-10 2 
VTP
56
  22 12 8 2 9 <1 2 
VMPT
54
 38 22 10 5 4 13 - 
MPR
17
 35° 11° 3° 1 - 9
#
 7§ 
MAINTENANCE 
VT
54,55
 0-3 0 0 1 4-7 2 - 
VP
56
 0 0 0 0 2 2 - 
Rd
58
 28 8 18 8 1 29 3 
R
17
 2° 6° 2° 2 - 3
#
 7§ 
 
 
 
MPR, melphalan-prednisone-lenalidomide; MPT, melphalan-prednisone-thalidomide; R, lenalidomide; Rd, lenalidomide-dexamethasone; VMP, bortezomib-melphalan-prednisone; VMPT, bortezomib-
melphalan-prednisone-thalidomide; VP, bortezomib-prednisone; VT, bortezomib-thalidomide; VTP, bortezomib-thalidomide-prednisone.  
- Data not available; *Data retrieved from the source studies; § For the whole MPR-R regimen; # Grade 3 events only; ° Grade 4 events only.  
 
 
 
 
 
 
 
 
 
 
